ClinicalTrials.gg
CompletedNCT00937872Updated Jun 5, 2017

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

A Phase 1 interventional study of 250 mg SRT2104 Suspension and Carbon-14 radio-labeled SRT2104 in Diabetes Mellitus, Type 2, sponsored by Sirtris, a GSK Company. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Sirtris, a GSK Company (part of GlaxoSmithKline) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2008, registered Jul 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · GlaxoSmithKline.

Enrollment
116th of 125
9 · median 70
Started
2008
with 9 others
Phase 1
51 of 136
none open now
Registered
74th of 136
by date

Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 116th largest by enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2008, is one of 51 in phase 1, and was the 74th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline as a file.
02

Study summary

The primary objective of this study is to determine the absolute bioavailability of SRT2104 as a 250 mg suspension, and to define the intravenous pharmacokinetics of SRT2104.

The secondary objective of this study is to assess the potential systemic metabolite burden of SRT2104, and to provide plasma and urine samples for subsequent metabolite profiling and identification.

Read the detailed description

This will be a single centre, combined IV and oral single dose, open-label study in healthy male volunteers.

Each subject will receive the following formulations on a single study day:

  1. Regimen A: A single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation;
  2. Regimen B: A single intravenous dose of 10 mL containing 100 µg (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104 , administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose.
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males;
  • Aged 18-65 years;
  • (BMI) of 18-35 kg/m2;
  • Willing and able to participate in the whole study and must provide written .

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical research study involving drugs or dosage forms within the previous 4 months;
  • Subjects who have previously been enrolled in this study;
  • Subjects who have ever sought advice from or been referred to a GP or counselor for abuse or misuse of alcohol, non medical drugs, medicinal drugs or other substance abuse e.g. solvents;
  • Subjects who admit to any current or previous use of Class A drugs such as opiates, cocaine, ecstasy, lysergic acid diethylamide (LSD) and intravenous amphetamines (Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs of abuse test and have been abstinent for at least 12 months;)
  • Positive drugs of abuse test result (Section 7.8);
  • Regular alcohol consumption in males >21 units per week (1 Unit = ½ pint beer, a 25 mL shot of 40% spirit or a 125 mL glass of wine);
  • Current smokers and those who have smoked within the last 12 months.
  • A breath carbon monoxide reading of greater than 10 ppm at screening;
  • Radiation exposure from clinical trials, including that from the present study and from diagnostic x rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;
  • abnormal biochemistry, haematology or urinalysis as judged by the PI (Section 7.8 )
  • History of adverse reaction or allergy to study drug or its , e.g. lactose.
  • History of significant allergy. If subject suffers from hayfever they must not have or be expecting to have symptoms during the study period;
  • Donation of blood within the previous three months;
  • Subjects will be excluded from the study if they are considered by the PI to be at risk of transmitting, thorough blood or other body fluids, the agents responsible for acquired immunodeficiency syndrome (AIDS) or other sexually transmitted disease or hepatitis;
  • Positive , or results;
  • Subjects receiving prohibited medication as described in Section 6.10;
  • Clinically significant medical history, examination finding or laboratory abnormality which in the opinion of the Investigator makes the subject unsuitable to include in the study;
  • Failure to satisfy the PI of fitness to participate for any other reason.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    SRT2104

    Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.

    Drug: 250 mg SRT2104 Suspension · Drug: Carbon-14 radio-labeled SRT2104

Interventions

  • Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.

  • Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability of SRT2104 250 mg suspension.

    Time frame: Time points to measure the bioavailability of SRT2104 oral 250 mg suspension: 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72 hrs following administration.

  2. Define the intravenous pharmacokinetics of SRT2104.

    Time frame: Time points to define the IV PK of SRT2104: Just before infusion (0); During infusion (5, 10 min); Post infusion (5, 10, 20, 30, 45 min and 1, 2, 3, 4, 6, 8, 10, 12, 15, 21, 45, 69 hours).

Secondary outcomes

  1. Potential systemic metabolite burden of SRT2104 following administration.

    Time frame: At time points: Pre-dose; 0-12 hrs post dose; 12-24 hrs post dose).

07

Study locations

1 site
  • GSK Investigational Site
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Dec 2008, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2009
First posted
Jul 13, 2009
StartActual
Nov 22, 2008
Primary completionActual
Dec 22, 2008
CompletionActual
Dec 22, 2008
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00937872
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 13, 2009
Start date
Nov 22, 2008
Primary completion
Dec 22, 2008
Completion
Dec 22, 2008
Last update
Jun 5, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SRT2104 · Carbon-14

Start the discussion